SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Hemminki Kari) srt2:(2015-2019)"

Sökning: WFRF:(Hemminki Kari) > (2015-2019)

Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
51.
  • Campo, Chiara, et al. (författare)
  • Bortezomib-induced peripheral neuropathy : A genome-wide association study on multiple myeloma patients
  • 2018
  • Ingår i: Hematological Oncology. - John Wiley and Sons Ltd. - 0278-0232. ; 36:1, s. 232-237
  • Tidskriftsartikel (refereegranskat)abstract
    • The proteasome-inhibitor bortezomib was introduced into the treatment of multiple myeloma more than a decade ago. It is clinically beneficial, but peripheral neuropathy (PNP) is a side effect that may limit its use in some patients. To examine the possible genetic predisposing factors to PNP, we performed a genome-wide association study on 646 bortezomib-treated German multiple myeloma patients. Our aim was to identify genetic risk variants associated with the development of PNP as a serious side effect of the treatment. We identified 4 new promising loci for bortezomib-induced PNP at 4q34.3 (rs6552496), 5q14.1 (rs12521798), 16q23.3 (rs8060632), and 18q21.2 (rs17748074). Even though the results did not reach genome-wide significance level, they support the idea of previous studies, suggesting a genetic basis for neurotoxicity. The identified single nucleotide polymorphisms map to genes or next to genes involved in the development and function of the nervous system (CDH13, DCC, and TENM3). As possible functional clues, 2 of the variants, rs12521798 and rs17748074, affect enhancer histone marks in the brain. The rs12521798 may also impact expression of THBS4, which affects specific signal trasduction pathways in the nervous system. Further research is needed to clarify the mechanism of action of the identified single nucleotide polymorphisms in the development of drug-induced PNP and to functionally validate our in silico predictions.
  •  
52.
  • Campo, Chiara, et al. (författare)
  • Genetic Susceptibility to Bortezomib-Induced Peripheral Neuroropathy : Replication of the Reported Candidate Susceptibility Loci
  • 2017
  • Ingår i: Neurochemical Research. - Springer. - 0364-3190. ; 42:3, s. 925-931
  • Tidskriftsartikel (refereegranskat)abstract
    • The introduction of proteasome inhibitors in the treatment of multiple myeloma (MM) patients has been a therapeutic success. Peripheral neuropathy (PNP) remains one of the most frequent side-effects experienced by patients who receive these novel agents. Recent investigations on the mechanisms of PNP in patients treated with bortezomib have suggested genetic susceptibility to neurotoxicity. We used data from a genome-wide association study conducted on 646 bortezomib-treated German MM patients to replicate the previously reported associations between single-nucleotide polymorphisms (SNPs) in candidate genes and PNP in MM patients, including 298 SNPs with a nominal significance (p value <0.05). Twelve associations were confirmed at a significance level p value <0.05. The corresponding SNPs are located in genes involved in drug metabolism (ABCC1, ABCC6), development and function of the nervous system (POGZ, NFAT pathway, EDN1), modulation of immune responses (IL17RD, IL10RA) and the NF-κB signaling pathway (PSMB4, BTCR, F2). We systematically investigated functional consequences of those variants using several bioinformatics tools, such as HaploRegV4.1, RegulomeDB and UCSC Genome Browser. Expression quantitative trait loci (eQTL) data suggested that some of the identified SNPs might influence gene expression through a differential recruitment of transcription factors. In conclusion, we confirmed some of the recently reported associations between germline variation and PNP. Elucidating the mechanisms underlying these associations will contribute to the development of new strategies for the prevention or reduction of PNP.
  •  
53.
  • Campo, Chiara, et al. (författare)
  • Inherited variants in genes somatically mutated in thyroid cancer
  • 2017
  • Ingår i: PLoS ONE. - Public Library of Science. - 1932-6203. ; 12:4
  • Tidskriftsartikel (refereegranskat)abstract
    • Background Tumour suppressor genes when mutated in the germline cause various cancers, but they can also be somatically mutated in sporadic tumours. We hypothesized that there may also be cancer-related germline variants in the genes commonly mutated in sporadic well-differentiated thyroid cancer (WDTC). Methods We performed a two-stage case-control association study with a total of 2214 cases and 2108 healthy controls from an Italian population. By genotyping 34 single nucleotide polymorphisms (SNPs), we covered a total of 59 missense SNPs and SNPs located in the 5' and 3' untranslated regions (UTRs) of 10 different genes. Results The Italian1 series showed a suggestive association for 8 SNPs, from which three were replicated in the Italian2 series. The meta-analysis revealed a study-wide significant association for rs459552 (OR: 0.84, 95%CI: 0.75-0.94) and rs1800900 (OR: 1.15, 95%CI: 1.05-1.27), located in the APC and GNAS genes, respectively. The APC rs459552 is a missense SNP, located in a conserved amino acid position, but without any functional consequences. The GNAS rs1800900 is located at a conserved 5'UTR and according to the experimental ENCODE data it may affect promoter and histone marks in different cell types. Conclusions The results of this study yield new insights on WDTC, showing that inherited variants in the APC and GNAS genes can play a role in the etiology of thyroid cancer. Further studies are necessary to better understand the role of the identified SNPs in the development of WDTC and to functionally validate our in silico predictions.
54.
  • Catalano, Calogerina, et al. (författare)
  • Investigation of single and synergic effects of NLRC5 and PD-L1 variants on the risk of colorectal cancer
  • 2018
  • Ingår i: PLoS ONE. - Public Library of Science. - 1932-6203. ; 13:2
  • Tidskriftsartikel (refereegranskat)abstract
    • Constitutive activation of interferon signaling pathways has been reported in colorectal cancer (CRC), leading to a strong CD8+ T cell response through stimulation of NLRC5 expression. Primed CD8+ T cell expansion, however, may be negatively regulated by PD-L1 expression. Additionally, aberrant PD-L1 expression enables cancer cells to escape the immune attack. Our study aimed to select potential regulatory variants in the NLRC5 and PD-L1 genes by using several online in silico tools, such as UCSC browser, HaploReg, Regulome DB, Gtex Portal, microRNA and transcription factor binding site prediction tools and to investigate their influence on CRC risk in a Czech cohort of 1424 CRC patients and 1114 healthy controls. Logistic regression analysis adjusted for age and gender reported a moderate association between rectal cancer risk and two NLRC5 SNPs, rs1684575 T>G (OR: 1.60, 95% CI: 1.13–2.27, recessive model) and rs3751710 (OR: 0.70, 95% CI: 0.51–0.96, dominant model). Given that a combination of genetic variants, rather than a single polymorphism, may explain better the genetic etiology of CRC, we studied the interplay between the variants within NLRC5, PD-L1 and the previously genotyped IFNGR1 and IFNGR2 variants, to evaluate their involvement in the risk of CRC development. Overall we obtained 18 pairwise interactions within and between the NLRC5 ad PD-L1 genes and 6 more when IFNGR variants were added. Thirteen out of the 24 interactions were below the threshold for the FDR calculated and controlled at an arbitrary level q*<0.10. Furthermore, the interaction IFNGR2 rs1059293 C>T—NLRC5 rs289747 G>A (P<0.0001) remained statistically significant even after Bonferroni correction. Our data suggest that not only a single genetic variant but also an interaction between two or more variants within genes involved in immune regulation may play important roles in the onset of CRC, providing therefore novel biological information, which could eventually improve CRC risk management but also PD-1-based immunotherapy in CRC.
55.
  • Catalano, Calogerina, et al. (författare)
  • Short article : Influence of regulatory NLRC5 variants on colorectal cancer survival and 5-fluorouracil-based chemotherapy
  • 2018
  • Ingår i: European Journal of Gastroenterology and Hepatology. - Lippincott Williams & Wilkins. - 0954-691X. ; 30:8, s. 838-842
  • Tidskriftsartikel (refereegranskat)abstract
    • Background NLRC5 is an interferon γ-inducible protein, which plays a role in immune surveillance with a potential influence on cancer survival. Objective We aimed to evaluate the effect of potential regulatory variants in NLRC5 on overall survival and survival after 5-fluorouracil (5-FU)-based therapy of colorectal cancer (CRC) patients. Patients and methods We carried out a case-only study in a Czech population of 589 cases; 232 received 5-FU-based therapy. Eleven variants within NLRC5 were selected using in-silico tools. Associations between polymorphisms and survival were assessed by Cox regression analysis adjusting for age at diagnosis, sex, and TNM stage. Survival curves were derived using the Kaplan-Meier method. Results Two variants showed a significant association with survival. All patients and metastasis-free patients at the time of diagnosis (pM0) who were homozygous carriers of the minor allele of rs27194 had a decreased overall survival (OS all and OS pM0) and event-free survival (EFS pM0) under a recessive model (OS all P=0.003, OS pM0 P=0.005, EFS pM0 P=0.01, respectively). OS was also decreased for all patients and for pM0 patients who carried at least one minor allele of rs289747 (OS all P=0.03 and OS pM0 P=0.003, respectively). Among CRC patients, who underwent a 5-FU-based adjuvant regimen, rs12445252 was associated with OS all, OS pM0 and EFS pM0, according to the dosage of the minor allele T (OS all P=0.0004, OS pM0 P=0.0001, EFS pM0 P=0.008, respectively). Conclusion Our results showed that polymorphisms in NLRC5 may be used as prognostic markers of survival of CRC patients, as well as for survival in response to 5-FU treatment.
  •  
56.
  •  
57.
  • Chattopadhyay, Subhayan, et al. (författare)
  • Enrichment of B cell receptor signaling and epidermal growth factor receptor pathways in monoclonal gammopathy of undetermined significance : a genome-wide genetic interaction study
  • 2018
  • Ingår i: Molecular Medicine. - The Feinstein Institute for Medical Research. - 1528-3658. ; 24:1
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: Recent identification of 10 germline variants predisposing to monoclonal gammopathy of undetermined significance (MGUS) explicates genetic dependency of this asymptomatic precursor condition with multiple myeloma (MM). Yet much of genetic burden as well as functional links remain unexplained. We propose a workflow to expand the search for susceptibility loci with genome-wide interaction and for subsequent identification of genetic clusters and pathways.METHODS: Polygenic interaction analysis on 243 cases/1285 controls identified 14 paired risk loci belonging to unique chromosomal bands which were then replicated in two independent sets (case only study, 82 individuals; case/control study 236 cases/ 2484 controls). Further investigation on gene-set enrichment, regulatory pathway and genetic network was carried out with stand-alone in silico tools separately for both interaction and genome-wide association study-detected risk loci.RESULTS: Intronic-PREX1 (20q13.13), a reported locus predisposing to MM was confirmed to have contribution to excess MGUS risk in interaction with SETBP1, a well-established candidate predisposing to myeloid malignancies. Pathway enrichment showed B cell receptor signaling pathway (P < 5.3 × 10- 3) downstream to allograft rejection pathway (P < 5.6 × 10- 4) and autoimmune thyroid disease pathway (P < 9.3 × 10- 4) as well as epidermal growth factor receptor regulation pathway (P < 2.4 × 10- 2) to be differentially regulated. Oncogene ALK and CDH2 were also identified to be moderately interacting with rs10251201 and rs16966921, two previously reported risk loci for MGUS.CONCLUSIONS: We described novel pathways and variants potentially causal for MGUS. The methodology thus proposed to facilitate our search streamlines risk locus-based interaction, genetic network and pathway enrichment analyses.
58.
  • Chattopadhyay, Subhayan, et al. (författare)
  • Genome-wide interaction and pathway-based identification of key regulators in multiple myeloma
  • 2019
  • Ingår i: Communications Biology. - Nature Research. - 2399-3642. ; 2:1
  • Tidskriftsartikel (refereegranskat)abstract
    • Inherited genetic susceptibility to multiple myeloma has been investigated in a number of studies. Although 23 individual risk loci have been identified, much of the genetic heritability remains unknown. Here we carried out genome-wide interaction analyses on two European cohorts accounting for 3,999 cases and 7,266 controls and characterized genetic susceptibility to multiple myeloma with subsequent meta-analysis that discovered 16 unique interacting loci. These risk loci along with previously known variants explain 17% of the heritability in liability scale. The genes associated with the interacting loci were found to be enriched in transforming growth factor beta signaling and circadian rhythm regulation pathways suggesting immunoglobulin trait modulation, TH17 cell differentiation and bone morphogenesis as mechanistic links between the predisposition markers and intrinsic multiple myeloma biology. Further tissue/cell-type enrichment analysis associated the discovered genes with hemic-immune system tissue types and immune-related cell types indicating overall involvement in immune response.
59.
  • Chen, Tianhui, et al. (författare)
  • Distribution and risk of the second discordant primary cancers combined after a specific first primary cancer in German and Swedish cancer registries.
  • 2015
  • Ingår i: Cancer Letters. - Elsevier. - 1872-7980. ; 369:1, s. 152-166
  • Tidskriftsartikel (refereegranskat)abstract
    • We aimed at investigating the distribution and risk of all second discordant primary cancers (SDPCs) after a specific first primary cancer in Germany and Sweden to provide etiological understanding of SDPCs and insight into their incidence rates and recording practices. Among 1,537,004 survivors of first primary cancers in Germany and 588,103 in Sweden, overall 80,162 and 32,544 SDPCs were recorded, respectively. Standardized incidence ratios (SIRs) of all SDPCs were elevated at levels between 1.1 and 2.1 after 23 (out of overall 29) cancers in Germany and at levels between 1.1 and 1.6 after 24 cancers in Sweden, and among them, elevated SIRs were found after 19 cancers in both populations. Decreased SIRs at levels ranging from 0.5 to 0.9 were found for some cancers with poor prognosis in Germany only. We found elevated risk after 19 out of 29 cancers in both countries, suggesting common etiology of SDPCs after most of first cancers and registration similarity. Decreased risks after some fatal cancers were found only in Germany, which may be attributed to reporting practices or missed death data in Germany.
  •  
60.
  •  
Skapa referenser, mejla, bekava och länka
Åtkomst
fritt online (74)
Typ av publikation
tidskriftsartikel (152)
Typ av innehåll
refereegranskat (150)
övrigt vetenskapligt (14)
Författare/redaktör
Hemminki, Kari, (152)
Försti, Asta, (86)
Sundquist, Kristina, (55)
Sundquist, Jan, (39)
Goldschmidt, Hartmut ... (26)
Thomsen, Hauke, (25)
visa fler...
Hoffmann, Per (24)
Weinhold, Niels, (23)
Hemminki, Akseli, (23)
Houlston, Richard S. (21)
da Silva Filho, Migu ... (17)
Yu, Hongyao, (17)
Sud, Amit, (17)
Nöthen, Markus M (16)
Chattopadhyay, Subha ... (16)
Hemminki, Otto, (15)
Zheng, Guoqiao, (15)
Chen, Bowang (14)
Jöckel, Karl-Heinz (13)
Fallah, Mahdi, (13)
Vodickova, Ludmila, (13)
Vodicka, Pavel, (13)
Morgan, Gareth J. (12)
Houlston, Richard (11)
Chen, Tianhui (11)
Kumar, Rajiv (10)
Frank, Christoph, (10)
Mitchell, Jonathan S (10)
Li, Xinjun, (9)
Pettersson-Kymmer, U ... (9)
Broderick, Peter (9)
Campo, Chiara, (9)
Orlando, Giulia, (9)
Hemminki, K (8)
Hansson, Markus, (8)
Ohlsson, Claes (8)
Engert, Andreas, (8)
Johnson, David C. (8)
Vymetalkova, Veronik ... (8)
Kharazmi, Elham (8)
Heidenreich, Barbara (8)
Law, Philip J. (8)
Nilsson, Björn, (7)
Naccarati, Alessio (7)
Hallmans, Göran (7)
Ji, Jianguang, (7)
Landi, Stefano, (7)
Huhn, Stefanie (7)
Holroyd, Amy (7)
Kaiser, Martin, (7)
visa färre...
Lärosäte
Lunds universitet (140)
Umeå universitet (9)
Karolinska Institutet (9)
Göteborgs universitet (7)
Uppsala universitet (2)
Språk
Engelska (152)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (152)

År

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy